Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioregenx (BRGX) Debt to Equity (2021 - 2025)

Bioregenx (BRGX) has 5 years of Debt to Equity data on record, last reported at -$0.05 in Q3 2025.

  • For Q3 2025, Debt to Equity fell 133.11% year-over-year to -$0.05; the TTM value through Sep 2025 reached -$0.05, down 133.11%, while the annual FY2024 figure was -$0.6, 37.51% down from the prior year.
  • Debt to Equity reached -$0.05 in Q3 2025 per BRGX's latest filing, up from -$0.31 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.15 in Q3 2024 and bottomed at -$2.37 in Q4 2021.
  • Average Debt to Equity over 5 years is -$0.32, with a median of -$0.08 recorded in 2022.
  • Peak YoY movement for Debt to Equity: soared 309.76% in 2024, then tumbled 3315.82% in 2025.
  • A 5-year view of Debt to Equity shows it stood at -$2.37 in 2021, then surged by 96.67% to -$0.08 in 2022, then tumbled by 450.0% to -$0.44 in 2023, then plummeted by 37.51% to -$0.6 in 2024, then surged by 91.7% to -$0.05 in 2025.
  • Per Business Quant database, its latest 3 readings for Debt to Equity were -$0.05 in Q3 2025, -$0.31 in Q2 2025, and -$0.32 in Q1 2025.